HURA
TuHURA Biosciences, Inc./NV
$2.44
-0.01 (-0.41%)
At close · Jul 2
Market Cap
$155.39M
Shares
63,682,528
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.44
Open$2.48
Day$2.43–2.56
52W$0.41–3.90
Avg vol 30d583K
Short int7.8M · 12.2% float · 16.6d
Short vol24%
Last earningsMay 15, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+30% above
+
Price vs 50-day avg
+5% above
◦
RSI (14)
53 · neutral
+
MACD trend
positive
◦
52-week position
58% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
+
Institutional flow
+35% holders QoQ · +29 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
12.19% of float · ▼ -8.0% MoM · 16.6 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
88 holders — near 1-yr high, broad support
Fundamentals
Strong
+
EPS growth
+48% Y/Y
−
Free cash flow
$-27.7M
+
Balance sheet
net cash $3.6M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Sep 29, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+30% above
Bullish
Price vs 50-day avg
+5% above
Bullish
RSI (14)
53 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
58% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+35% holders QoQ · +29 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.19% of float · ▼ -8.0% MoM · 16.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
88 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $2 · 58%
52-wk high $4
vs 200-day avg +30%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HURA
this stock
TuHURA Biosciences, Inc./NV
|
$155.39M | +222.3% | — | — | 12.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HURA | -5.8% | +15.1% | +223.2% | +4.3% | +222.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -7.2% | +16.3% | +215.2% | +4.5% | +213.1% |